Scientists in Spain have found a new molecule, called EPB-53 could help fight Type 2 diabetes and the non-alcoholic fatty liver disease. According
Fractyl Laboratories, a private medical technology company based in Lexington, Mass. has started the company’s first U.S. clinical trial for its
Losing a single night’s sleep may affect the liver’s ability to produce glucose and process insulin, increasing the risk of metabolic
Increasing the amount of protein in the diet may reduce the liver’s fat content and lower the risk of diabetes in people with non-alcoholic
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of liver disease in the United States. NAFLD is a condition in
Fatty liver disease is becoming increasingly common in many parts of the world, affecting about 25% of people globally. It is linked to obesity, type
Get a little dLife delivered to your inbox every week.
Leave this field empty if you’re human: